Commentary: An <i>In Silico</i> - <i>In Vitro</i> Pipeline Identifying an HLA-A*02:01<sup>+</sup> KRAS G12V<sup>+</sup> Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients. | Front Immunol;12: 523906, 2021. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Commentary: An In Silico - In Vitro Pipeline Identifying an HLA-A*02:01⁺ KRAS G12V⁺ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients.

Beer, Ilan.

Affiliation

Beer I; Adicet Bio Inc., Menlo Park, CA, United States.

Front Immunol ; 12: 523906, 2021.

Article in En | MEDLINE | ID: mdl-34326832

Subject(s)
Key words

HLA; KRAS mutation; mass spectrometry; peptide splicing; proteasome

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins p21(ras) / Neoplasms Limits: Humans Language: En Journal: Front Immunol Year: 2021 Document type: Article Affiliation country: Estados Unidos

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins p21(ras) / Neoplasms Limits: Humans Language: En Journal: Front Immunol Year: 2021 Document type: Article Affiliation country: Estados Unidos